Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Silence Therapeutics (SLN – Research Report). The associated price target remains the same with $75.00.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Silence Therapeutics’ promising future. The company’s strategic focus and strong financial position are key elements, with a cash runway extending into 2027, allowing for the advancement of its RNAi pipeline in rare diseases. The delay in the Phase 3 cardiovascular outcomes trial for zerlasiran is seen as a prudent move, pending a partnership that could unlock its blockbuster potential.
Additionally, the emergence of divesiran as a near-term value driver, with Phase 2 enrollment expected by the end of 2025, adds to the company’s growth prospects. The potential partnership announcement for zerlasiran and the progression of SLN548 into clinical development are viewed as significant catalysts that could drive the stock towards the $75 price target. Overall, Silence Therapeutics is well-positioned for significant upside, supported by its differentiated approach to Lp(a) lowering and the absence of approved pharmacological treatments for elevated Lp(a), affecting a substantial portion of the U.S. adult population.
In another report released on March 4, BMO Capital also maintained a Buy rating on the stock with a $25.00 price target.